SK bioscience's Covid-19 vaccine candidate won approval recommendation from the Central Pharmaceutical Affairs Council (CPAC) under the Ministry of Food and Drug Safety.
SK Bioscience’s Covid-19 vaccine candidate demonstrated statistically meaningful results confirming safety and immunogenicity in Phase 1 and 2 clinical trials.
SK Bioscience is set to speed up its global Phase 3 clinical trials of its GBP510 Covid-19 vaccine candidate.
SK Bioscience’s Covid-19 vaccine candidate GBP510 won approval to start Phase 3 clinical trials, the company said Tuesday.
Korea JoongAng Daily Sitemap
